• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • PROs
    • Menopause Rating Scale
      • Menopause Rating Scale (MRS) – Languages
    • Aging Male Symptoms Scale
      • AMS – properties as an outcome measure
      • AMS – properties as a screening tool
    • Quality of Sexual Function Scale
      • Quality of Sexual Function Scale
    • Short Term Hormone Effect Scale
      • Short Term Hormone Effect Scale
    • Research team
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Development

Development followed international guidelines for quality of life scales

The original MRS was designed to provide physicians with a scale that documented changes in climacteric symptoms during treatment 1.  Initital feedback from women suggested that the initial scale did not accurately capture sensitive information, limiting both its theorectical and practical use 2. Subsequent revisions of the scale incorporated the the following key points:

  • scale verification in a representative population
  • development of a patient-reported outcome questionnaire that sensitively addresses sexual-health symptoms unlikely to be divulged to medical professionals
  • modification of the scale so that it can be understood by consumers (laypersons)
  • psychometric analysis of the collected data and development of simple-to-use evaluation aids,
  • provision of a classification of complaints derived from an examination of the normal population, e.g. for comparisons with special patient groups.

The MRS was formally standardized according to psychometric rules. It consists of a list of 11 symptoms; respondent have a choice among 5 categories: no symptom, mild, moderate, marked, and severe.

During the standardization of the MRS, three independent dimensions were identified explaining 58.8% of the total variance (factor analysis): psychological, somato-vegetative, and urogenital sub-scale.

Each of the eleven symptoms contained in the scale can get 0 (no symptom) or up to 4 scoring points (severe symptom) depending on the severity of the complaints perceived by the women completing the scale (an appropriate box is to be ticked). The total score of the MRS ranges between 0 (asymptomatic) and 44 (highest degree of complaints). The minimal/maximal scores vary between the three dimensions depending on the number of complaints allocated to the respective dimension of symptoms:

  • sychological sub-scale
  • somato-vegetative domain
  • urogenital domain

A simple evaluation and scoring scheme

Evaulation and scoring is straightforward: the score increases point by point with increasing severity of subjectively perceived complaints in each of the 11 items (severity expressed in 0 – 4 points in each item).

By checking these 5 possible boxes of “severity” for each of the items the respondent provides his personal perception.

The total score of the MRS ranges between 0 (asymptomatic) and 44 (highest degree of complaints).

The minimal/maximal scores vary between the three dimensions depending on the number of complaints allocated to the respective dimension of symptoms:

  • psychological symptoms: 0 to 16 scoring points ( 4 symptoms: depressed, irritable, anxious, exhausted) somato-vegetative
  • symptoms: 0 to 16 points (4 symptoms: sweating/flush, cardiac complaints, sleeping disorders, joint & muscle complaints)
  • urogenital symptoms: 0 to 12 points (3 symptoms: sexual problems, urinary complaints, vaginal dryness).

The composite scores for each of the dimensions (sub-scales) is based on adding up the scores of the items of the respective dimensions.

The composite score (total score) is the sum of the dimension scores. The three dimensions, their corresponding questions and the evaluation are detailed and summarized here.


1. Hauser GA, Huber IC, Keller PJ, Lauritzen C, Schneider HPG: Evaluation der klinischen Beschwerden (Menopause Rating Scale). Zentralbl Gynakol 1994; 116:16-23.

2. Potthoff P, Heinemann LAJ, Schneider HPG, Rosemeier HP, Hauser GA. Menopause-Rating Skala (MRS): Methodische Standardisierung in der deutschen Bevölkerung. Zentralbl Gynakol 2000; 122:280-286.

sidebar

Expertise

  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
    • Aging Male Symptoms Scale
    • Menopause Rating Scale
    • Scale for Quality of Sexual Function
    • Short Term Hormone Effect Scale
    • Research team
  • Data collection instruments

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2025 ZEG Berlin

Impressum

Website by Laura Yeffeth.